Patents Assigned to OncoMethylome Sciences, S.A.
-
Publication number: 20150017634Abstract: The present invention relates to methods and kits for identifying, diagnosing, prognosing, and monitoring cervical cancer. These methods include determining the methylation status or the expression levels of particular genes, or a combination thereof.Type: ApplicationFiled: February 13, 2014Publication date: January 15, 2015Applicant: Oncomethylome Sciences S.A.Inventors: Wim Van Criekinge, Valerie Deregowski, Luc Dehaspe, G. Bea A. Wisman, Ate G.J. Van der Zee, E. M.D. Schuuring
-
Publication number: 20120196827Abstract: Using a combination of analytic methods epigenetic silencing of markers in cancer have been determined. The cancers are generally those of the gastrointestinal tract including but not limited to esophageal, head and neck, gastric, pancreas, liver, and colon. The genes can be used for the early detection of cancer or can be used to identify adenomas that will likely progress to carcinomas. Therapeutic regimens based on the epigenetic silenced genes can be chosen and/or monitored. Kits for evaluating epigenetic silencing of these genes can be used for detection and monitoring.Type: ApplicationFiled: June 12, 2007Publication date: August 2, 2012Applicant: ONCOMETHYLOME SCIENCES S.A.Inventors: Wim Van Criekinge, Gerrit Meijer, Josef Straub, Beatriz Pinto Morais De Carvalho
-
Publication number: 20100035970Abstract: Two hundred ten markers are provided which are epigenetically silenced in one or more cancer types. The markers can be used diagnostically, prognostically, therapeutically, and for selecting treatments that are well tailored for an individual patient. Restoration of expression of silenced genes can be useful therapeutically, for example, if the silenced gene is a tumor-suppressor gene. Restoration can be accomplished by supplying non-methylated copies of the silenced genes or polynucleotides encoding their encoded products. Alternatively, restoration can be accomplished using chemical demethylating agents or methylation inhibitors. Kits for testing for epigenetic silencing can be used in the context of diagnostics, prognostics, or for selecting “personalized medicine” treatments.Type: ApplicationFiled: April 17, 2006Publication date: February 11, 2010Applicants: Oncomethylome Sciences, S.A., The Johns Hopkins UniversityInventors: Wim Van Criekinge, Josef Straub, David Sidransky
-
Publication number: 20090215709Abstract: Two hundred ten markers are provided which are epigenetically silenced in one or more cancer types. The markers can be used diagnostically, prognostically, therapeutically, and for selecting treatments that are well tailored for an individual patient. Restoration of expression of silenced genes can be useful therapeutically, for example, if the silenced gene is a tumor-suppressor gene. Restoration can be accomplished by supplying non-methylated copies of the silenced genes or polynucleotides encoding their encoded products. Alternatively, restoration can be accomplished using chemical demethylating agents or methylation inhibitors. Kits for testing for epigenetic silencing can be used in the context of diagnostics, prognostics, or for selecting “personalized medicine” treatments.Type: ApplicationFiled: October 13, 2006Publication date: August 27, 2009Applicants: Johns Hopkins University, OncoMethylome Sciences, S.A.Inventors: Wim Van Criekinge, Josef Straub, David Sidransky
-
Patent number: 7507536Abstract: Twenty-three markers are provided which are epigenetically silenced in ovarian cancers. The markers can be used diagnostically, prognostically, therapeutically, and for selecting treatments that are well tailored for an individual patient. Restoration of expression of silenced genes can be useful therapeutically, for example, if the silenced gene is a tumor-suppressor gene. Restoration can be accomplished by supplying non-methylated copies of the silenced genes or polynucleotides encoding their encoded products. Alternatively, restoration can be accomplished using chemical demethylating agents or methylation inhibitors. Kits for testing for epigenetic silencing can be used in the context of diagnostics, prognostics, or for selecting “personalized medicine” treatments.Type: GrantFiled: October 6, 2006Date of Patent: March 24, 2009Assignees: The Johns Hopkins University, OncoMethylome Sciences, S.A.Inventors: Wim Van Criekinge, Josef Straub, Nathalie Sieben
-
Publication number: 20080221056Abstract: We have developed a transcriptome-wide approach to identify genes affected by promoter CpG island hypermethylation and transcriptional silencing in colorectal cancer (CRC). By screening cell lines and validating tumor specific hypermethylation in a panel of primary human CRC samples, we estimate that nearly 5% of all known genes may be promoter methylated in an individual tumor. When directly compared to gene mutations, we find a much larger number of genes hypermethylated in individual tumors, and much higher frequency of hypermethylation within individual genes harboring either genetic or epigenetic changes. Thus, to enumerate the full spectrum of alterations in the human cancer genome, and facilitate the most efficacious grouping of tumors to identify cancer biomarkers and tailor therapeutic approaches, both genetic and epigenetic screens should be undertaken. The genes we identified can be used inter alia diagnostically to detect cancer, pre-cancer, and likelihood of developing cancer.Type: ApplicationFiled: February 12, 2008Publication date: September 11, 2008Applicants: JOHNS HOPKINS UNIVERSITY, ONCOMETHYLOME SCIENCES, S.A.Inventors: Stephen B. Baylin, Wim Van Criekinge, Kornel E. Schuebel